Lode Debrabandere, Ph.D., President and Chief Executive Officer, joined Osiris in July 2006. Prior to joining Osiris, Dr. Debrabandere served for over four years with Bristol-Myers Squibb as Vice President of Strategic Marketing for Neuroscience and Infectious Diseases. He led the Neuroscience Unit and was the Global Brand Leader for Abilify™. Previously, Dr. Debrabandere led the Marketing department of UCB Pharma Inc., focusing in the areas of allergy/respiratory (Zyrtec™) and neurology (Keppra™). Dr. Debrabandere earned an MBA, a Ph.D. in pharmaceutical sciences, toxicology, and a Pharm. D. degree, all from the University of Leuven, Belgium.
Philip R. Jacoby, Jr., Chief Financial Officer and Corporate Secretary, joined Osiris in April 2005. Mr. Jacoby previously served as the Company’s Controller and Chief Accounting Officer. From 1999 to 2004, Mr. Jacoby served as Vice President and Corporate Controller for FTI Consulting, Inc., a global business financial and economic consulting firm. Mr. Jacoby began his career with Arthur Andersen & Co., and earned his undergraduate degree in business and public administration from the University of Maryland.
Frank D. Czworka, Jr., Vice President and General Manager of Wound Care, joined Osiris in August 2011. Mr. Czworka has over 20 years of sales and marketing experience in the Life Science industry with a demonstrated track record of building specialty sales forces and developing product access in managed markets, including public and private payer accounts. Prior to Osiris, he served as Vice President of Sales at MedImmune, responsible for leading a 450 person sales team for Synagis®, a $1B monoclonal antibody for RSV and FluMist®, the first intranasal influenza vaccine. He also led sales efforts at other biotech organizations including TAP Pharmaceuticals and Auxilium Pharmaceuticals. Mr. Czworka holds a bachelor's degree in Marketing from the University of Central Florida.
Dwayne Montgomery, General Manager Orthopedics and Sports Medicine, joined Osiris April 2014. Mr. Montgomery brings over 20 years medical device experience in global commercial operations and strategic planning. Prior to joining Osiris, Mr. Montgomery served as the Senior Vice-President of Sales and Marketing for IlluminOss Medical where he was responsible for worldwide commercialization within the orthopedic trauma market. Mr. Montgomery also held progressing roles of executive responsibility at Smith & Nephew, Inc., serving as Vice President of Sales & Marketing for the Clinical Therapies Global Business, a division that eventually became Bioventus, Inc., and Vice President and General Manager for the Orthopedics Global Trauma Business –with full P&L responsibility, he led a commercial team of 435 professionals and generating over $400 million in yearly revenue. Mr. Montgomery earned a Bachelor of Science Degree in Chemistry from the University of North Alabama and a M.B.A. from the Massey School of Business at Belmont University.
Alla Danilkovitch, Ph.D., Vice President Research and Development, joined Osiris in April 2003. Dr. Danilkovitch has over 25 years of a broad biomedical research experience including stem cell biology, immunology and cancer research. She has a proven record of successful product development from scientific ideas to market launch, which includes the world's first approved stem cell drug, Prochymal, for graft versus host disease as well as Osiris' current line of products. Prior to joining Osiris, Dr. Danilkovitch conducted research at the following institutions: National Cancer Institute of National Institutes of Health, Max-Plank Institute of Biochemistry in Munich (Germany), Eotvos Lorand University in Budapest (Hungary) and Moscow State University (Russia). Dr. Danilkovitch earned a Ph.D. degree in cell biology and an M.S. degree in cellular immunology and microbiology from the Moscow State University. She also holds a R.N. degree in pediatrics with an intensive care experience at Moscow's province general hospital in Russia.
Therésa K. Dixon, General Manager of Market Access and Reimbursement, joined Osiris in March 2014.Ms. Dixon has 20 years of market access and reimbursement experience in the life science industry with a demonstrated track record of establishing positive market access for a broad range of medical devices, pharmaceuticals and biologics as well as creating successful market access teams. Prior to joining Osiris, she served as Vice President of Government Affairs & Health Economics for Shire, as well as extensive experience in establishing market access at Smith & Nephew, Covance and Express Scripts. Ms. Dixon holds an M.B.A. from the University of Maryland, an M.S. in Health Care Management from Marymount University, and a B.A. from the University of Missouri - Columbia.
Douglas Jacobstein, M.D., Senior Medical Director, joined Osiris in February 2009. Dr. Jacobstein has served as Medical Director in gastroenterology at UCB, Inc. and was Director of Clinical Development and Medical Affairs at Alba Therapeutics. Prior to joining industry, Dr. Jacobstein was a practicing pediatric gastroenterologist with clinical and research interests in the use of disease modifying biologics for inflammatory diseases of the gastrointestinal tract. Dr. Jacobstein is certified by the American Board of Pediatrics in Pediatric Gastroenterology. He completed his fellowship in gastroenterology at the Children’s Hospital of Philadelphia (CHOP) and residency at St. Christopher’s Hospital for Children. Dr. Jacobstein earned his Bachelor’s degree from Cornell University and his medical degree from the University of Maryland.